Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 30;8:421. doi: 10.3389/fphar.2017.00421

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Zheng, Feng, Liu, Guo, Gao, Li, Xu, Yan, Yin, Zhang, Liu and Shan.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

6-phosphogluconate dehydrogenase offers superiority for cisplatin resistance. Proposed working model.(A) In cisplatin-resistant cancer cells, miRNA-206 and miRNA-613 are commonly downregulated in cisplatin-resistant cells, leading to reduced expression levels of 6PGD. And reprogramming cell metabolism, including NADPH/NADP+ ratio, lactate production and intracellular ATP levels, to fulfill cancer cells resistant to cisplatin treatment. (B) Attenuation of 6PGD by miRNAs or small molecule inhibitor Physcion results in decreased 6PGD expression or enzyme activity, leading to cancer cell sensitive to cisplatin treatment.